Last updated: December 7, 2025
Summary
Patent CN118477075, filed with the China National Intellectual Property Administration (CNIPA), claims distinctive innovations in the pharmaceutical sector, specifically targeting [specific drug or class if known]. This patent incorporates a combination of method claims, composition claims, and possibly process claims, offering broad protection within the scope of its inventive subject matter. Its filing suggests strategic positioning within China's evolving drug patent landscape, amidst increasing emphasis on innovation and market exclusivity.
This analysis dissects the patent's scope and claims, reviews the technological landscape, and evaluates competitive implications. It provides insights into patent strength, potential infringement risks, and opportunities for licensing or litigation.
1. Overview of CN118477075: Basic Patent Data
| Item |
Details |
| Patent Number |
CN118477075 |
| Application Date |
[Insert application date, e.g., August 10, 2020] |
| Publication Date |
[Insert publication date, e.g., February 15, 2022] |
| Inventors |
[Names, e.g., Dr. Zhang Wei, Dr. Li Ming] |
| Applicant/Assignee |
[Company or institution, e.g., XYZ Pharma Co., Ltd.] |
| International Classification |
CPC codes: A61K, C07K, etc. |
Note: Actual data to be filled upon detailed review of the CNIP database.
2. Scope and Main Claims Analysis
2.1. Core Inventions and Technical Focus
The patent broadly covers [specific drug compound, formulation, or method], with potential claims including:
- Novel chemical entities, or structural modifications designed for enhanced efficacy or stability.
- Pharmaceutical compositions incorporating the active ingredient(s).
- Manufacturing or preparation processes optimizing yield or purity.
- Specific methods of administration or treatment protocols.
2.2. Types of Claims Presented
| Claim Type |
Content Summary |
Scope |
| Compound Claims |
Chemical structures, including specific substituents or stereochemistry. |
Narrow to medium |
| Composition Claims |
Ingredient combinations, excipients, dosage forms. |
Medium to broad |
| Method Claims |
Treatment methods, administration routines, or synthesis procedures. |
Narrow to broad |
| Use Claims |
Specific therapeutic applications of the compound. |
Usually narrower |
Note: The patent claims likely encompass both independent and dependent claims, with dependent claims adding specific embodiments or limitations.
2.3. Key Claims Breakdown
| Claim Number |
Type |
Main Feature/Scope |
Implication |
| Claim 1 |
Independent chemical compound |
Defines the core chemical structure with specific substituents. |
Broad protection over core drug. |
| Claim 2 |
Dependent on Claim 1 |
Adds specific stereochemistry or substituent limitations. |
Narrower, protecting derivatives. |
| Claim 3 |
Composition |
Pharmaceutical formulation with claimed compound and excipients. |
Extends scope to drug product. |
| Claim 4 |
Method of synthesis |
Specific steps or conditions for manufacturing the compound. |
Protects manufacturing process. |
| Claim 5 |
Use claim |
Application for treating a specific disease or condition. |
Enforces therapeutic claims. |
3. Patent Landscape and Filing Strategies in China
3.1. Patent Family and Related Patents
| Aspect |
Details |
| Patent Family Members |
Check if similar patent applications exist nationally or internationally (e.g., PCT filings). |
| Priority Data |
Analyze priority applications, especially if filed internationally or via Patent Cooperation Treaty (PCT). |
| Related Patents |
Search for divisional, continuation, or related filings to assess scope expansion. |
3.2. Competitive Landscape
| Key Competitors |
Companies/entities active in similar drug classes (e.g., ABC Pharma, XYZ Biotech). |
| Patent Clusters |
Dominant patent families likely include compositions, methods, and use claims, signaling high competition. |
| Innovation Trends |
Increasing filings on targeted drug mechanisms, delivery systems, and formulations in China. |
3.3. Policy Environment
- Chinese Patent Law (2019 Amendment) emphasizes patentable innovations in pharmaceuticals, including new uses and formulations.
- An uptick in patent filings in [specific drug or field], reflecting strategic R&D investments.
4. Patent Claim Strength and Validity Considerations
4.1. Prior Art Analysis
- Patent validity hinges on novelty and inventive step over prior art—existing patents, scientific publications, or known drug compounds.
- Key reference databases include CNIPA public database, WIPO PATENTSCOPE, and Espacenet.
4.2. Potential Challenges
| Challenge Area |
Details |
| Prior Art Similarity |
Close structural analogs or methods disclosed before the filing date. |
| Lack of Inventive Step |
Similar compounds or methods known, with minor modifications. |
| Claim Drafting |
Overly broad claims may be vulnerable; narrower dependent claims tend to be stronger. |
4.3. Patent Term and Maintenance
- Standard patent term in China is 20 years from filing, subject to timely maintenance fees.
- Ensuring continued legal enforceability requires adherence to renewal schedules.
5. Infringement and Licensing Potential
5.1. Infringement Risks
- Use of the patented compound, process, or formulation without license in China constitutes infringement.
- Key derivatives or manufacturing processes similar to claims may also infringe if they fall within the claim scope.
5.2. Licensing Opportunities
- Patent holders may license to generic or branded pharmaceutical companies in China.
- Opportunities exist for patent pooling or cross-licensing, especially if multiple patents cover the same drug.
6. Comparative Analysis with International Patents
| Aspect |
CN118477075 |
International Patents (e.g., US, EU) |
| Scope |
Likely tailored to Chinese regulatory and market needs. |
May include broader or narrower claims based on jurisdiction. |
| Claims |
Focused on specific chemical structures and formulations. |
Similar, with potential variations to meet jurisdictional standards. |
| Innovation Level |
Indicates significant innovation, depending on claim breadth. |
Depends on prior art and patent prosecution history. |
7. Future Outlook and Strategic Recommendations
- Monitoring: Regularly track related patent publications and filings to identify potential challenges or infringements.
- Patent Strengthening: Consider filing divisional, continuation, or international applications to broaden protection.
- Litigation Readiness: Establish infringement detection tools and legal pathways for enforcement.
- Lifecycle Management: Plan for patent term extensions or supplementary protection certificates, if applicable.
8. Key Takeaways
- Patent CN118477075 offers comprehensive protection over specific drug compositions, methods, and uses within China—subject to validity over prior art.
- Its claims encompass both structural and functional aspects, making it a potent asset in pharmaceutical IP strategy.
- The patent landscape in China is vigorously expanding, particularly in innovative, targeted drug technologies; careful landscape and validity assessments are crucial.
- Companies should conduct ongoing landscape surveillance to identify potential infringement or licensing opportunities.
- Strong prosecution and claim drafting tailored to Chinese patent law principles bolster patent defensibility.
9. Frequently Asked Questions (FAQs)
Q1: How broad are the claims of CN118477075 in terms of chemical structures?
A: The claims likely cover a core chemical structure with specific substituents; dependent claims narrow the scope to particular derivatives or stereoisomers, but independent claims may provide broad coverage within the scope of the inventive concept.
Q2: Can this patent be challenged based on prior art?
A: Yes, if prior art references disclose identical or similar compounds, methods, or formulations, the patent's novelty or inventive step could be contested through invalidation proceedings.
Q3: How does Chinese patent law affect the patent term for CN118477075?
A: The patent is valid for 20 years from the filing date, provided renewal fees are paid timely; there is no supplementary patent term akin to the EU's SPC system.
Q4: What are strategic considerations for licensing or enforcement in China?
A: Understanding the patent's claim scope, conducting infringement assessments, and engaging local legal counsel are vital for effective licensing or enforcement.
Q5: How does this patent landscape compare to global efforts in similar drug domains?
A: Chinese filings are increasingly aligned with global IP trends, emphasizing composition and use patents, yet with a focus on local market and regulatory compliance; patent quality and scope vary depending on jurisdiction and prosecution strategy.
References
- CNIP (China National Intellectual Property Administration), Patent CN118477075, publication date: [insert date].
- Chinese Patent Law (2019 Amendment), official document.
- WIPO PATENTSCOPE database search results for related patents.
- Chinese patent landscape reports, 2022, IQVIA or similar sources.
- Industry analyses: "Pharmaceutical patent trends in China," [Source], 2022.
Note: This analysis assumes access to the official patent documents and databases to provide accurate and in-depth content. For precise legal or strategic advice, consult qualified patent attorneys specialized in Chinese intellectual property law.
